Table 3.

Comparison of Selected Participant Characteristics in Patients Who Had Conventional Treatment and then Burosumab Treatment

Variables	Conventional treatment (n = 19)	Burosumab treatment (n = 19)	p
Sex, n (%)
Male	7 (36.9)	7 (36.9)
Female	12 (63.1)	12 (63.1)	1
Age at XLH treatment onset (years), mean ± SD	2.10 ± 2.07	9.75 ± 2.92	<0.0001
XLH treatment duration (months), mean ± SD	90.8 ± 36.3	35.0 ± 7.1	<0.0001
Alkaline phosphatase level (IU/L), mean ± SD	451.0 ± 147.2	297.8 ± 100.2	<0.0001
Age at dental follow‐up onset (years), mean ± SD	6.60 ± 3.67	10.36 ± 3.11	<0.0001
Dental follow‐up duration (months), mean ± SD	37.2 ± 27.8	27.7 ± 8.1	0.19
Number of dental abscess per month of dental follow‐up (n/month), mean ± SD	0.08 ± 0.1	0.007 ± 0.02	0.01
Number of maxillofacial cellulitis per month of dental follow‐up (n/month), mean ± SD	0.005 ± 0.02	0.002 ± 0.009	0.43
Dental caries during dental follow‐up, n (%)	2 (10.5)	4 (21.0)	0.68